Sensei Biotherapeutics (NASDAQ:FTH) Now Covered by Analysts at Raymond James Financial

Raymond James Financial started coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research report released on Friday, MarketBeat.com reports. The brokerage issued an outperform rating and a $56.00 price objective on the stock.

FTH has been the topic of a number of other reports. Weiss Ratings initiated coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. HC Wainwright began coverage on Sensei Biotherapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $60.00 price objective for the company. Loop Capital set a $50.00 target price on Sensei Biotherapeutics in a research report on Thursday, May 28th. Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.89.

Sensei Biotherapeutics Stock Down 5.5%

NASDAQ:FTH opened at $27.24 on Friday. Sensei Biotherapeutics has a 52 week low of $7.10 and a 52 week high of $37.90. The stock has a market capitalization of $36.56 million, a price-to-earnings ratio of -0.19 and a beta of -0.26.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. Equities analysts forecast that Sensei Biotherapeutics will post -16.61 earnings per share for the current year.

Insider Buying and Selling

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 25,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the transaction, the insider directly owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Anand Kiran Parikh acquired 2,806 shares of Sensei Biotherapeutics stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $19.76 per share, with a total value of $55,446.56. Following the completion of the acquisition, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This trade represents a 0.37% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have purchased 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is owned by company insiders.

Institutional Trading of Sensei Biotherapeutics

Several hedge funds have recently made changes to their positions in FTH. Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics during the 1st quarter valued at $22,758,000. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics in the 1st quarter worth about $4,188,000. Bank of America Corp DE increased its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares during the period. 10.50% of the stock is currently owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.